EA200801942A1 - Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон - Google Patents

Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон

Info

Publication number
EA200801942A1
EA200801942A1 EA200801942A EA200801942A EA200801942A1 EA 200801942 A1 EA200801942 A1 EA 200801942A1 EA 200801942 A EA200801942 A EA 200801942A EA 200801942 A EA200801942 A EA 200801942A EA 200801942 A1 EA200801942 A1 EA 200801942A1
Authority
EA
Eurasian Patent Office
Prior art keywords
risk
reducing
cancer
occuration
belses
Prior art date
Application number
EA200801942A
Other languages
English (en)
Inventor
Пол А. Авербэк
Джек Джеммелл
Original Assignee
Наймокс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Наймокс Корпорейшн filed Critical Наймокс Корпорейшн
Publication of EA200801942A1 publication Critical patent/EA200801942A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Раскрытое здесь изобретение описывает способы предотвращения или уменьшения риска развития рака в ткани, железе, органе или другой клеточной массе млекопитающего путем удаления или разрушения нежелательных клеток, используя для этой цели соединения, содержащие или основанные на пептидах Белка Нервной Нити.
EA200801942A 2006-03-10 2007-03-12 Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон EA200801942A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78082906P 2006-03-10 2006-03-10
PCT/CA2007/000402 WO2007104149A1 (en) 2006-03-10 2007-03-12 Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides

Publications (1)

Publication Number Publication Date
EA200801942A1 true EA200801942A1 (ru) 2009-02-27

Family

ID=38508997

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801942A EA200801942A1 (ru) 2006-03-10 2007-03-12 Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон

Country Status (11)

Country Link
US (1) US20070237780A1 (ru)
EP (1) EP2007410A4 (ru)
JP (1) JP2009529503A (ru)
KR (1) KR20080108530A (ru)
CN (1) CN101400364A (ru)
AU (1) AU2007224971A1 (ru)
BR (1) BRPI0708737A2 (ru)
CA (1) CA2643239A1 (ru)
EA (1) EA200801942A1 (ru)
MX (1) MX2008011570A (ru)
WO (1) WO2007104149A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
KR101835860B1 (ko) 2015-10-30 2018-03-09 순천향대학교 산학협력단 난소암 또는 경계성 난소종양의 예방 또는 치료용 조성물 및 진단용 마커 조성물
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
CN1582301A (zh) * 2001-05-25 2005-02-16 尼莫克斯股份有限公司 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
JP4587667B2 (ja) * 2001-07-19 2010-11-24 ナイモックス コーポレーション 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Also Published As

Publication number Publication date
US20070237780A1 (en) 2007-10-11
BRPI0708737A2 (pt) 2011-06-14
EP2007410A4 (en) 2009-10-21
CN101400364A (zh) 2009-04-01
AU2007224971A1 (en) 2007-09-20
WO2007104149A1 (en) 2007-09-20
CA2643239A1 (en) 2007-09-20
KR20080108530A (ko) 2008-12-15
JP2009529503A (ja) 2009-08-20
MX2008011570A (es) 2008-09-23
EP2007410A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
EA200801942A1 (ru) Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
CY1119509T1 (el) Συνθεσεις και μεθοδοι για ρυθμιστες αποπτωσης
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BRPI0516727A (pt) métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
CY1113199T1 (el) Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
GT201200189A (es) Antagonistas de pcsk9
BRPI0511995A (pt) uso de compostos peptìdicos para tratamento de dor em neuralgia trigeminal
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
EA201070812A1 (ru) Лечение и профилактика амилоидоза
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
TW200714283A (en) Method and composition for treating peripheral vascular diseases
SG170750A1 (en) Stabilized polypeptide compositions
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
BRPI0607009A2 (pt) stent endoureteral absorvìvel composto reforçada com fibra
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
EA200702193A1 (ru) Гликозилирование белков
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2008034016A3 (en) Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
EP2195331A4 (en) SYNTHETIC APOLIPOPROTEIN RECIPIENTS AND METHOD OF USE
TW200716132A (en) Novel chemical compounds
BRPI0815460A2 (pt) kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos